Mosunetuzumab and epcoritamab demonstrated response rates and survival outcomes comparable to clinical trial findings in a real-world setting.

Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found tolerable and showed signs of efficacy in a real-world cohort. Delandistrogene ...

Ontada will present a real-world research study at the ASCO Annual Meeting examining GLP-1 receptor agonist utilization and overall survival outcomes.

Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse ...

Researchers share their experience with sotatercept in 91 patients with pulmonary arterial hypertension, the first report on outcomes outside clinical studies.

Sensitive skin affects up to 70% of people globally – a figure that has risen by 68% over the past two decades – yet it remains widely overlooked and under-studied. 2,3 As more people live fast-paced ...

Nearly half of advanced ovarian cancer patients relapsed after first-line PARP inhibitor maintenance, emphasizing the need for refined postrecurrence strategies. BRCA mutation carriers were more ...

Erleada significantly reduces the risk of death by 51% in mCSPC patients compared to Nubeqa, without chemotherapy, over 24 months. The study used inverse probability of treatment weighting to ensure ...

Real-world studies assess treatment effectiveness and patient experience beyond clinical trial settings, considering broader patient populations. Clinical trials have stricter enrollment criteria, ...